Trandolapril/verapamil (Tarka) is an oral antihypertensive medication that combines a slow release formulation of verapamil hydrochloride, a calcium channel blocker, and an immediate release formulation of trandolapril, an ACE inhibitor. The patent, held by Abbott Laboratories, expired on February 24, 2015. This combination medication contains angiotensin-converting enzyme (ACE) inhibitor and calcium channel blocker and is prescribed for high blood pressure. References
External links
"Trandolapril mixture with verapamil hydrochloride". Drug Information Portal. U.S. National Library of Medicine.
Society and culture
Legal status
On 16 December 2021, the Committee for Medicinal Products for Human Use (CHMP)  of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Kerendia, intended for the treatment of chronic kidney disease associated with type 2 diabetes in adults. The applicant for this medicinal product is Bayer AG. Finerenone was approved for medical use in the European Union in February 2022. Research
In the Phase II ARTS-DN study, finerenone dose-dependently reduced urine albumin to creatinine ratio in patients with diabetic kidney disease. Based on these findings, finerenone is being studied in the large Phase III FIDELIO and FIGARO outcome studies designed to assess whether finerenone reduces risk of CKD progression and adverse cardiovascular events in patients with Chronic Kidney Disease and Type 2 Diabetes. These trials have enrolled more than 13,000 patients with primary completion of FIDELIO anticipated in 2020 and FIGARO IN 2021. References
Further reading
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P,  et al. (December 2020). "Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes". N Engl J Med. 383 (23): 2219–2229. doi:10.1056/NEJMoa2025845. PMID 33264825. External links
"Finerenone". Drug Information Portal. U.S. National Library of Medicine.